Angiotensin II (ANG) promotes cell proliferation and angiogenesis as well as being a potent vasoconstrictor. The cellular distribution of renin, ANG and its receptors in the endometrium has yielded useful information about the possible role of the renln-angiotensin system hi cyclic menstruation. In the early proliferative phase, intense ANG-like immunostaining was detected in stroma and glandular epithelia, whereas in the late secretory phase, maximal immunoreactivity was localized in the perivascular stromal cells around the endometrial blood vessels. Quantitative receptor autoradiographic studies demonstrated that the human endometrium contains predominantly ANG type 2 receptor (AT2), with a relatively low expression of ANG type 1 receptor (ATj) and a novel non-AT 1 /non-AT 2 ANG recognition site. AT receptors displayed cyclic changes, and the highest renin concentration was detected in the late secretory phase prior to menstruation. After long-term Norplant® treatment, an increase in ANG-like immunoreactivity was observed in endometrial stroma and glandular epithelia, while in hyperplastic endometrium, ANG-like immunoreactivity decreased compared with normal cyclic endometria. The pattern of ANG immunostaining in endometria from patients with irregular menstruation was markedly different from that detected in normal endometrium. Normal function of the renin-angiotensin system in endometrium may be necessary for regular cyclic menstruation, and alterations in the distribution of ANG and/or the activity of its receptors are likely to be involved in dysfunctional uterine bleeding.
Introduction
Regular bleeding is a feature of the normal menstrual cycle in women. Menstruation usually arises after orderly changes that occur in both the histological and biological development of the endometrium under the regulation of ovarian steroids. However, very little is known about the local biochemical and cellular events leading to the physiological disruption, repair and regeneration of blood vessels during the menstrual cycle. The commencement of menstruation is characterized by intense vasoconstriction of the spiral arterioles (Markee, 1940) . Following the onset of menstrual bleeding, the upper functional layer of the endometrium is shed, and cessation of bleeding is achieved by vasoconstriction of the remaining basal arteriolar fragments (Christiaens etaL, 1980) . This vasoconstriction is essential until blood loss is stemmed by regeneration of the vessels and surrounding tissue.
The increased incidence of irregular, prolonged and other bleeding problems experienced by users of subdermal contraceptive implants remains unexplained. In women receiving Norplant®, there is an increase in the endometria] microvascular density compared with controls (Rogers et aL, 1993) , and in ovariectomized rats, vascular density increases during endometrial regression (Rogers and Macpherson, 1990) . Therefore it is likely that the local mechanisms involved in the development of X.-F.LJ and A Ahmed non-vascular endometrial components are different from those controlling vascular development. Despite the fact that the mechanisms regulating the endometrial vessels are poorly understood, it is increasingly clear that local mediators play an important role in menstruation and irregular bleeding.
The precise nature of the endometrial vasoconstrictor which initiates menstruation has not been established. Prostaglandin F^ and, more recently, endothelin have been suggested as possible candidate endometrial vasoconstrictors (Maigaard et al., 1985; Cameron and Davenport, 1992) . However, prostaglandin F^ is usually a relatively weak pressor agent (Maigaard et al, 1985) . Endothelin has been found to cause a potent long-lasting contraction of the human uterine artery and vein (Fried and Samuelson, 1991) ; however, the effects of endothelin on small myometrial or endometrial vessels have not been documented. O'Reilly et al. (1992) reported differences in the ratio of endothelin A and endothelin B receptor mRNA activities in proliferative and secretory endometrium using reverse transcription polymerase chain reaction, but the functional relevance of these changes remain unclear. Endothelin is co-mitogenic for a variety of cell types, including vascular smooth muscle cells. However, specific actions of endothelin on endometrial proliferation or angiogenesis await demonstration (Cameron and Davenport, 1992) . Tabibzadeh et al. (1995) recently reported that fragmentation of the endometrial glands during menstruation is associated with disorganization and/or loss of the proteins at the adherens and desmosomal junctions, as well as a loss of F-actin. However, it is unclear whether these disorganizations are causes or results of menstruation. Osuga et al (1995) reported the presence of plateletderived endothelial cell growth factor (PD-ECGF) in human endometrium. Its characteristic expressions during the menstrual cycle and early gestational period suggest that PD-ECGF may play a physiological role as an angiogenic factor in the decidualization of human endometrium. Several angiogenic factors, including basic fibroblast growth factor (Cordon-Cardo etaL, 1990) , vascular endothelial growth factor (Li et al, 1994) , transforming growth factor a (Horowitz et al, 1993) , transforming growth factor {$ (Kauma et al, 1990) and tumour necrosis factor a (Tabibzadeh, 1991) have also been demonstrated to be present in the endometrium. However, their functional roles in endometrium have not been detailed.
Angiotensin II (ANG) is an octapeptide and historically has been associated with the homeostatic regulation of fluid and electrolyte balance and with peripheral vascular resistance. More recent studies suggest that it acts as an angiogenic growth factor in the regeneration of new blood vessels (Fernandez et al, 1985; LeNoble et al, 1991 LeNoble et al, , 1993 . The administration of ANG to rabbit cornea (Fernandez et al, 1985) or chick embryo chorioallantoic membrane (LeNoble et al, 1993) induced pronounced neovascularization, and ANG can be a direct stimulus for cell growth (Baker and Aceto, 1990) . The renin-angiotensin system cascade stimulates new vessel formation, in which ANG acts as a growth factor, triggering cellular hypertrophy, stimulating cell replication and causing pronounced angiogenesis of pre-and post-capillary vessels (Molloy et al, 1993) . ANG interacts with specific high-affinity receptors on the surface of target cells to exert its biological effects. There are at least two major classes of angiotensin receptor, referred to as ATi and AT 2 (Wong et al, 1990) . Most of the physiological effects of ANG, including vasoconstriction, renal electrolyte transport, steroidogenesis and prostaglandin production, are attributable to AT] receptors. The AT 2 receptor is linked to the stimulation of phosphotyrosine phosphatase (PTPase) activity and is involved in the control of cell proliferation and differentiation (Bottari et al., 1993) .
The endometrium has the potential to produce large quantities of angiotensins (Johnson, 1980a) . Studies in the myometrium (Schirartf al, 1980) and placenta (Kurauchi et al, 1989) show that ANG receptors are regulated by oestrogen and progesterone. Endometrial stromal cells are a significant source of active renin, and progesterone induces a marked increase in its production (Shah et al, 1991) . The maximum potential to produce angiotensins coincides with triggering of the events of menstruation. Therefore ANG may be a crucial local factor in the endometrium because intense vasoconstriction of the spiral arterioles is a prere- Figure 1 . Components of the renin-angiotensin system and pathways for their formation. ACE converting enzyme; AT = angiotensin receptor type. angiotensin quisite for normal menstruation and the microvascular system responds with rapid capillary growth associated with endometrial regeneration following menstruation.
Components of the renin-angiotensin system
and pathways for their formation Figure 1 shows the main components and pathway for the formation of circulating renin-angiotensin systems. Renin is a glycoproteolytic enzyme synthesized by the juxtaglomerular apparatus of the kidneys. Once released into the circulation, renin acts on an aa-macroglycoprotein, angiotensinogen, which is continuously synthesized and released from the liver. The first 10 amino acids of angiotensinogen represent angiotensin I, which is released by the hydrolytic action of renin (Tewksbury et al., 1981) . The decapeptide angiotensin I is rapidly converted to the octapeptide ANG upon circulation through organs and in the plasma by the action of the predominantly endothelially located enzyme angiotensin converting enzyme (ACE). ANG is generated as a result of the loss of histidyl-leucine from the C-terminal end of angiotensin I by the action of ACE, and is generally assumed to be the biologically active component of the renin-angiotensin system. ANG inhibits renin release (Keeton and Campbell, 1980) and acts as a negative feedback mechanism controlling its own formation. It is a potent vasoconstrictor and can stimulate aldosterone biosynthesis in the adrenal zona glomerulosa, which provides an extremely rapid and efficient homeostatic response to acute changes in blood pressure, fluid and electrolyte status (Campbell, 1987) . ANG is degraded further to the heptapeptide, des-Asp-ANG (angiotensin IH) by non-specific aminopeptidases. Angiotensin HI is then degraded into fragments by a number of amino-, carboxy-and endopeptidases.
It was the use of peptide ligands, such as saralasin, and reducing agents, such as dithiothreitol, that first suggested the existence of multiple AT receptors. The development of nonpeptide antagonists provided direct evidence of AT receptor heterogeneity. The AT] receptor is sensitive to nanomolar concentrations of losartan {DuP753; (2-n-butyl-4-chloro-5-hydroxymethyl-1 -[2-( 1 H-tetrazol-5 -y l)bipheny l-4-yl)methy 1] -imidazole, DuPont Merck Pharmaceuticals}, which is ~10 000 times more selective for AT, sites compared with AT 2 sites. In contrast, the AT 2 receptor is sensitive to PD123177 {l-(4-amino-3-methylphenyl)methyl-5-diphenyl-acetyl-4,5,6,7-tetrahydro-lH-imidazo [4,5-C]pyridine-6-carboxylic acid), DuPont Merck Pharmaceutical}, which has a 3500-fold selectivity for AT 2 sites compared with AT, binding sites. Both the AT! (Murphy et al., 1991) and AT 2 (Mukoyama et al., 1993) receptors have been cloned and share an overall 32% sequence homology, although the transmem-brane regions show a somewhat higher degree of homology. The ATi receptor has a seven amino acid transmembrane region motif and belongs to the G protein-coupled receptor family (Sasaki et al., 1991) . It has been shown to regulate a series of second messengers, generating enzymes and ion transporting systems through G proteins, and is involved in the modulation of adenylate cyclase, the stimulation of phospholipase A 2 , phospholipase C and phospholipase D, and the regulation of Ca 2+ , K + and Cl" channels (Bottari et al, 1993) . AT! mediates the well-known pressor effect of ANG.
Until recently, there was no evidence to suggest either which signalling pathway was linked to AT2 receptors or the biological responses elicited by their stimulation. Recent studies (Bottari et al, 1993) have shown that AT 2 receptors mediate an ANG-induced decrease in intracellular cGMP in neuron cultures (Sumners et al, 1991) , and the AT 2 receptor is linked to the stimulation of PTPase activity (Bottari et al., 1993) . The activation of tyrosine phosphorylation via the AT 2 receptor (Bottari et al, 1992; Buisson et al., 1995; Nahmias et al, 1995) suggests that it may mediate processes such as cellular growth, differentiation and/or adhesion, because these processes involve cascades of tyrosine kinases and phosphatases. Meanwhile, the high and transient expression of the AT 2 receptor during fetal development (Grady et al, 1991) , followed by a dramatic drop just after birth in most organs, and re-expression in pathological conditions suggest that it may be involved in tissue remodelling or repair, such as vascular neointima formation and wound healing (Janiak et al, 1992; Viswanathan and Saavedra, 1992) . Studies have shown that administration of the AT 2 -specinc nonpeptide ligand, CGP 42112A, to rats could prevent the formation of neointima following artery injury (Janiak et al, 1992) , hence providing a close link between AT 2 receptors and vascular growth. In recent gene-targeted disruption studies, the mouse lacking AT 2 showed a significant increase in blood pressure (Ichiki et al, 1995) and increased sensitivity to the pressor action of ANG (Hein et al, 1995; Ichiki et al, 1995) , which indicated that AT 2 mediates a depressor effect and antagonizes the AT r mediated pressor action of ANG.
The occurrence and proportion of the AT, and AT 2 subtypes vary significantly among different tissues and organs of the same species, and also in the same tissues and organs of different species. The differential distribution of the AT t and AT 2 receptors has been identified. Receptor autoradiographic studies using subtype-selective antagonists and in-situ hybridization studies have shown that liver, lung, kidney, placenta, urinary bladder, gastrointestinal tract and aortic smooth muscle cells all express AT, receptors only (Entzeroth and Hadamovsky, 1991; Simon et al, 1991; Bunnemann et al, 1992) . In contrast, other tissues, such as pancreas and ovarian granulosa cells, express mainly AT 2 receptors (Pucell et al, 1991; Chappell et al, 1992) . Both receptor subtypes are expressed in the brain (Barnes et al, 1993) , adrenal glands (Whitebread et al, 1989) , heart (de Gasparo et al, 1990; Chang and Lord, 1991) , renal arteries (de Gasparo et al, 1990) and uterus (Whitebread et al, 1989; Ahmed et al, 1995) .
Renin-angiotensin system in human endometrium
There is increasing evidence in many tissues, including human ovaries (Palumbo et al, 1989) and human endometrium (Johnson, 1980a; Ahmed et al, 1995) , to suggest the existence of locally active tissue renin-angiotensin systems (Campbell, 1987) which operate, in whole or in part, independently of the circulating renin-angiotensin system.
Renin and ANG in human endometrium
Renin mRNA is expressed in human endometrium (Shaw et al, 1988) , and endometrial stroma cells are capable of synthesizing a renin-like substance (Symonds et al, 1968; Shah et al, 1991) . This suggests that endometrium acts as a primary source of renin production. Immunocytochemical studies have demonstrated renin immunostaining in endometrial stroma] and glandular cells, but no staining was seen in secretory endometrium. The negative reaction in these sections may relate to loss of antigenicity caused by formalin fixation (Raju and Lee, 1989) . Both iso-renin and renin substrate concentrations in the endometrium vary independently of those in the plasma, and both substances were found in much higher concentrations in the endometrium than in the plasma. Endometrium contains up to 200 times the concentration of plasma renin, which suggests that the endometrium has the potential to produce large quantities of angiotensin I (Johnson, 1980a) . ANG-like immunoreactivity was detected in human endometrium throughout the menstrual cycle, as described previously (Ahmed et al, 1995) . There was a marked difference in the pattern of staining between different phases of the menstrual cycle. During the early proliferative phase of the menstrual cycle, there was a heterogeneous staining of the stroma and glandular epithelium. Some of the stromal and glandular cells showed an intense brown granular cytoplasmic staining ( Figure 2A ). In the mid-proliferative phase, immunoreactivity was noted in a few cells of the stroma and glandular epithelium. Both these cell types showed very weak to moderate staining. The stroma and glands displayed no immunoreactivity to ANG in late proliferative endometrium. No obvious immunostaining was observed around the endometrial blood vessels throughout the proliferative phase. Positive staining was localized around the endometrial spiral arterioles during the early secretory phase, with negligible staining in glandular epithelium and stroma ( Figure 2C ). There was an increase in the intensity of staining around endometrial blood vessels during the mid-secretory phase, with minimal or entirely absent staining in the stroma. During the late secretory phase, the intensity of staining was enhanced and localized in the perivascular stromal cells ( Figure 2E ). Glandular epithelium showed weak staining and stroma appeared relatively negative to the primary antibody in the late secretory phase.
Most specimens from the Norplant-treated group were atrophic endometria. The ANG-like immunoreactivity was higher in the Norplant-treated endometrial stroma and glandular epithelia than in normal cyclic menstrual endometrium (X.F. Li and A.Ahmed, unpublished data) . However, there was very little or no immunostaining around thinwalled blood vessels ( Figure 3A ). Very intense staining was observed in glands which have small cuboidal epithelial cells and very little staining around the vessels ( Figure 3C ). No correlation could be established between immunostaining scores and the bleeding patterns or histological classification of the Norplant-treated biopsies because the number of specimens was too few.
The cellular distribution of ANG and its receptor subtypes (AT, and AT 2 ) in hypeiplastic endometria from patients who had dysfunctional uterine bleeding with or without progestogen treatment was investigated using immunocytochemistry and quantitative receptor autoradiography (Li and Ahmed, 1996) . ANG-like immunoreactivity decreased in the hypeiplastic endometrial stroma and glandular epithelia compared with normal cyclic endometria. ANG-like immunostaining was more intense in the progestogen-treated endometria compared with normal endometria. In the progestogen-treated endometrium from patients who had regular menstruation cycles, the ANG-like immunostaining was localized in the perivascular stromal cell, as seen in the normal cyclic endometrium. Both AT] and AT 2 receptor activities in the hypeiplastic and progesterone-treated endometria were significantly lower than those detected in normal endometrium.
Activity of AT receptors and their mRNA in human endometrium
ATj receptor mRNA was highly expressed in both endometrial glands and stroma of the proliferative endometrium (Ahmed et al., 1995) . The intensity of the hybridization signal decreased in the secretory endometrial stroma, while a strong hybridization signal was seen around the endometrial blood vessels (Ahmed et al., 1995) . (Figure 4 ). There was a very low activity of AT] receptors and a small amount of non-AT]/ non-AT 2 receptor subtypes in human endometrium. The mean activity of AT 2 receptor-specific binding in normal endometrium increased from the midto the late proliferative phase (Ahmed et aL, 1995) ( Figure 5 ). AT2 binding reached maximum values in the early secretory phase, and then decreased during the mid-and late secretory phases. The cyclic changes in the mean values of AT] receptorspecific binding paralleled AT 2 receptor-specific binding values (Figure 6 ). AT, and AT 2 receptor subtypes are not distributed uniformly in tissues and species (Chappell et al, 1992) . Some tissues have a nearly homogeneous distribution of AT] or AT 2 receptors, while others are characterized by a mixture of both receptor subtypes (Kurauchi et al., 1989; Whitebread et al, 1989; Edwards et al., 1992) .
Endometrial sections incubated with [
125 I]ANG in the presence of DuP753 and PD123177 showed low activities of a novel binding site, which we have termed the non-AT] and AT 2 ANG recognition site (Ahmed etaL, 1995) . Several lines of evidence exist to suggest that there may be more than two subtypes of ANG receptor and that there may be variations in the structure of both the AT] and AT 2 subtype (Bottari et al, 1993) . This evidence is based on structure-activity studies using non-peptide analogues of ANG. The evidence for a novel ANG receptor involved in angiogenesis in chick embryo chorioallantoic membrane has also been reported (LeNoble et al, 1993) .
Regulation of the renin-angiotensin system in the endometrium
Cyclic changes of ANG-like immunoreactivity in endometrial stroma and glandular epithelia and around endometrial blood vessels indicate that ANG activities are regulated by sex steroids (Ahmed et al, 1995) . In the early proliferative phase, renin concentrations were relatively high and then to decrease until immediately prior to menstruation (Johnson, 1980a) . The normal second-half cycle increase in renin concentration observed in ovulatory cycles was abolished in oral contraceptive-controlled cycles (Johnson, 1980b) . However, there was a pre-menstmal increase in renin substrate concentration in the endometrium in both oral contraceptive and normal cycles. The highest concentration of renin detected at the late stage of the menstrual cycle is paralleled by the maximal ANG-like immunoreactivity around blood vessels in late secretory endometria. Furthermore, the activities of total AT! and AT 2 receptor-specific binding in normal endometrium also showed cyclic changes, increasing from the early and mid-prouferative phases to maximal activities in the early secretory phase, and then decreasing in the midand late secretory phases. The cyclic changes in renin concentration, ANG immunoreactivity and activities of AT receptors indicated that sex steroids play a dual role in the control of the reninangiotensin system in human endometrium. Progesterone may up-regulate renin production and increase ANG activity, as well as down-regulate AT receptors in the endometrium, as reported previously in studies of the myometrium and placenta (Siddiqi et al, 1986; Shaw et al., 1988; Kurauchi et al., 1989) .
Endometria from Norplant-treated women exhibited an increased ANG immunoreactivity in stroma and glandular epithelium when compared with normal menstrual cycle endometria. This is consistent with the previous finding that endometrial stromal cells are a primary source of active renin and that progesterone induced a marked increase in its production (Shaw et al, 1988) . There was a marked decrease in active renin secretion when cell cultures were maintained over a 15 day period. The decrease in renin secretion was prevented by progesterone treatment in paired samples (Shah et al., 1991) . Increased concentrations of active renin, which is inducible by exogenous progestogen treatment, may lead to an increase in the renin-angiotensin system activity and result in a high endometrial ANG immunoreactivity. Therefore it is suggested that endometrial renin secretion is influenced in a paracrine fashion by progesterone, and that the local reproductive reninangiotensin system is under the control of ovarian sex steroids. In a previous study, oestradiol plus progesterone decreased the total number of rat placental ANG receptors, while oestradiol plus progesterone increased angiotensin concentrations (Kurauchi et al, 1989) . Myometrium is rich in ANG receptors and the uterus is highly sensitive to ANG (Siddiqi et al, 1986) . Low activities of ANG receptors in uterine myometrium were related to poor uterine contractility during labour (Geelhoed et al., 1970) . Oestrogen treatment increased ANG receptor activities and the sensitivity of uterine contractility, while progesterone treatment had the opposite effect. In non-pregnant rats, myometrial ANG receptors decreased in activity after the long-term infusion of oestradiol, whereas short-term infusions Figure 5. The activities of angiotensin type 2 (AT 2 >-specific binding sites in endometrial tissues from women with normal menstrual cycles at different phases of the cycle. Data represent the mean ± SE of the cases (n) of endometrial specimens studied. Significantly higher activities of AT r specific binding in early secretory phase endometrium were detected compared with those in endometria of the mid-proliferative, mid-secretory and late secretory phases. There was no significant difference in the AT 2 -specific binding activities between the early secretory and late proliferative phases. EP = early proliferative; MP m mid-proliferative; LP "» late proliferative; ES = early secretory; MS = mid-secretory; LS = late secretory. (*) P < 0.05; (••) P < 0.01; (•••) P < 0.001 (one-way analysis of variance followed by Dunnett's (-test, compared with the activity in early secretory phase endometrium). Reproduced from Ahmed et al (1995) by copyright permission of the American Society for Clinical Investigation.
Figure 2. Immunocytochemical localization of angiotensin II (ANG) in human endometrium with normal cyclic menstruation. Serial sections from early proliferative (A and B), early secretory (C and D) and late secretory (E and F) endometrium. (A) Section shows intense ANG immunostaining in the glandular epithelial cells (G) and stromal cells but without staining around blood vessels (Bv). (C) No immunostaining is shown in the endometrial glandular epithelia and stromal cells but ANG is imraunolocalized around endometrial blood vessels (arrowed). (E) Very intense staining is shown in the perivascular stroma around endometrial blood vessels (arrowed), but there is no staining in the endometrial glandular epithelium and stromal cells. (B-D) Negative controls. Scale bar = 20 urn for (AHD); 40 (im for (E) and (F). Reproduced from Ahmed
had the opposite effect (Schirar et al, 1980) . Progesterone infusions produced a marked decrease in the activity of myometrial ANG receptors (Schirar et al., 1980) . Similarly, our study has shown that the activities of AT] and AT 2 receptors in the endometrium decreased while the progesterone concentration increased during the secretory phase of menstrual cycles. These results suggest that ovarian steroids play an important role in the control of the number of angiotensin binding sites in human endometrium, and that ANG receptors are up-regulated by oestrogen and down-regulated by progestogens. The regulating effect of oestrogen and progesterone on the expression of the number of AT receptors indicates the possibility of a dual control on the endometrium at the levels of peptide formation and on the expression of its receptors.
The number of AT receptors in the anterior pituitary of the female rat was also dependent on the stage of the oestrous cycle. However, in contrast to the regulation in the endometrial stroma and placenta] tissue, oestrogen replacement in ovariec-0.00 J Figure 6 . The activities of angiotensin type 1 specific binding sites in endometrial tissues from women with normal menstrual cycles at different phases of the cycle. Data represent the mean ± SE of the cases (n) of endometrial specimens studied. Significantly higher activities of AT]-specific binding in early secretory phase endometrium were detected compared with those in endometria of the mid-proliferative, mid-secretory and late secretory phases. There was no significant difference in the ATj-specific binding activities between the early secretory and late proliferative phases. EP = early proliferative; MP = mid-proliferative; LP •» late proliferative; ES = early secretory; MS «• = mid-secretory; LS = late secretory. (*) P < 0.05 (one-way analysis of variance followed by Dunnett's f-test, compared with the activity in early secretory phase endometrium). Reproduced from Ahmed et al (1995) by copyright permission of the American Society for Clinical Investigation.
tomized rats decreased AT] receptor numbers in the anterior pituitary (Chen and Printz, 1983; Platia et al, 1986; Seltzer et al, 1992) . The physiological implication of the modulation of pituitary AT receptors by oestrogen is not known at present, but it is not surprising that the regulation of this system at the central level could be different from regulation at the peripheral tissue level. Cyclic changes in endometria] ANG immunoreactivity and AT receptors during the menstrual cycle indicate possible relationships between ANG metabolism and steroid hormones (Figure 7) . The nature of these relationships requires further investigation.
Possible function of the renin-angiotensin system in endometrium
ANG is widely recognized for its ability to stimulate adrenocortical aldosterone synthesis and to cause the contraction of vascular and non-vascular smooth muscle (Griendling et al, 1989; Molloy Endometrial Anglotensln II |. Figure 7 . Possible regulation by oestradiol (E) and progesterone (P) of the endometrial rcnin-angiotensin system.
et al, 1993) . The commencement of menstruation is characterized by intense vasoconstriction of the spiral arterioles (Andrade et al, 1992) . Following the onset of menstrual bleeding, the upper functional layer of the endometrium is shed, and cessation of bleeding is achieved by vasoconstriction of the remaining basal arteriolar fragments and re-epithelialization of the endometrium (Ludwig et al, 1990) . As ANG involves both vasoconstriction and the regeneration of new blood vessels, it may play a dual role in menstruation. Because of limitations of the human model, the role of the renin-angiotensin system in endometrial regeneration and the initiation of menstruation is based on the cellular distribution of renin, ANG and its receptors in the endometrium and by extrapolation from studies on other cell systems.
The intense ANG-like immunoreactivity seen around blood vessels in late secretory endometrium, together with earlier reports of a marked increase in the angiotensin-producing potential of the endometrium (Johnson, 1980a) , which coincides with the triggering events of menstruation, suggest that ANG may play a possible role in the initiation of menstruation by vasoconstriction of the spiral arterioles prior to menstruation. This vasoconstriction is essential for the control of endometrial bleeding until blood loss is stemmed by the regeneration of blood vessels and the surrounding tissues. The cyclic changes in ANG immunostaining observed around the endometrial blood vessels in normal endometrium were absent in most of the sections from the Norplant-treated groups, which were associated with irregular menstruation. This suggested that the normal localization of ANG in perivascular stromal cells may be a prerequisite for regular menstruation.
Because AT] receptor mediates the pressor effect of ANG while AT 2 mediates cell growth and angiogenesis, higher activities of AT] receptors in early to mid-proUferative endometrium and higher activities of AT 2 receptors in late secretory endometrium would be expected. However, a similar profile for AT] and AT 2 with a peak activity in early secretory endometrium was reported by Ahmed et al. (1995) . Further investigations are needed to provide direct evidence of different functions of AT receptor subtypes in human endometrium.
Role of ANG in dysfunctional endometrial
bleeding Dysfunctional uterine bleeding is defined as abnormal bleeding including irregular, prolonged, frequent and heavy menstruation with grossly normal pelvic organs and without a causative uterine lesion (such as a tumour, infection or complication of pregnancy). Dysfunctional uterine bleeding may occur with any type of endometrium, but most commonly with resultant hyperplasia (Novak and Woodroff, 1979) . Hyperplasia of the endometrium results from oestrogenic stimulation without the usual cyclic modification of progesterone. Therefore progestational agents usually result in elimination of the hyperplasia and abnormal uterine bleeding (Jones, 1988) . ANG-like immunoreactivity decreased in the hyperplastic endometrial stroma and glandular epithelia compared with normal cyclic endometria (Li and Ahmed, 1996) . The ANG-like immunostaining was more intense in progestogen-treated endometrium compared with normal endometrium. In the progestogen-treated endometrium of patients who had regular menstrual cycles, ANG-like immunostaining was localized in the perivascular stromal cell, as seen in the normal cyclic endometrium. Both AT] and AT 2 receptor activities in the hyperplastic and progesterone-treated endometria were significantly lower than those detected in normal endometrium (Li and Ahmed, 1996) . The result supports our earlier hypothesis that the normal function of ANG in endometrium may be essential for regular cyclic menstruation (Ahmed et al, 1995) , and indicates that alterations in the distribution of ANG and/or the activities of its receptors are likely to be involved in dysfunctional uterine bleeding associated with hyperplastic endometria.
Reduced spiral arteriole development and an increased number of dilated subepithelial venules after the use of low-dose progestogen-only contraceptive pills and levonorgestrel-releasing contraceptive vaginal rings have been reported (Hourihan et al., 1991) , which may be elucidated by our findings that a very weak ANG immunostaining was detected in the congested thin-walled blood vessels in the endometrial sections under Norplant treatment, while the stroma and glands showed high ANG immunoreactivities. Meanwhile, because of the poor development of endometrial spiral arterioles with very little ANG activity, intense vasoconstriction of the spiral arterioles cannot be achieved to initiate menstruation; therefore breakthrough bleeding occurs. Hence, these reasons may explain irregular prolonged menstruation or spotting.
In addition, ANG can act as a growth promoter, to either stimulate cell replication or trigger cellular hypertrophy through oncogene activation (Taubman et al., 1989) . During the early to mid-proliferative phase, when the endometrium undergoes rapid cell division, angiotensin-like immunoreactivity was confined to the stroma and glandular epithelium. The stroma and glandular epithelium showed a typical brown granular cytoplasmic staining, while there was no staining around the blood vessels. Because there is rapid capillary growth associated with endometrial regeneration following menstruation, it is possible that ANG may modulate cell growth and neovascularization directly or through the expression of other growth factors or proto-oncogenes. ANG has been reported to stimulate basic fibroblast growth factor expression in bovine luteal cells (Campbell, 1987) which stimulated endothelial cell proliferation . It was reported previously that ANG stimulated new vessel formation and played an important role in tumour angiogenesis during the development of glioblastoma multiform, which had the characteristic histological features of hyperplastic vascular endothelium (Ariza et al, 1988) .
ANG treatment of quiescent smooth muscle cells stimulates rapid tyrosine phosphorylation of a distinct set of cellular proteins. ANG can induce rapid changes in gene expression and function that may ultimately lead to increased cell growth (Molloy et al., 1993) .
It has been reported that there was significant angiogenesis in terms of growth of the coiled arteriolar system under the influence of luteal progesterone (Kaiserman-Abramof and Padykula, 1989) in primate endometrium. Human secretory phase endometrial explants have been shown to stimulate endothelial cell migration in vitro (Rogers et al., 1992) . Endometrium from women treated with Norplant had 162% of the vascular density of control endometrium (Rogers et al, 1993) . Thus it appears that progestogen can stimulate endometrial vascular growth, or at least maintain existing vascular networks, under certain conditions when the rest of the endometrium is regressing. Endometrial specimens from patients treated with Norplant displayed higher ANG immunoreactivities (X.-F. Li and A.Ahmed, unpublished data) . The increase in endometrial vascular density under the long-term treatment of Norplant is likely to be a result of higher ANG activity and its angiogenic effects.
Conclusions
These studies conclusively confirm the existence of a local tissue renin-angiotensin system in the endometrium and show that both ANG-like immunoreactivity and AT receptors are regulated by ovarian sex steroid hormones. Maximal ANG-like immunostaining seen around the endometrial blood vessels in the late secretory endometrium, together with the previous findings of a pre-menstrual increase in the endometrial renin concentration, strongly support the view that ANG is likely to be involved in spiral arteriole vasoconstriction prior to menstruation and in the initiation of cyclic bleeding. Furthermore, the intense ANG immunoreactivity in the stroma and glandular epithelium of proliferative endometrium indicates that ANG may be associated with cellular proliferation and angiogenesis during endometrial regeneration. These observations have led us to propose that this octapeptide may play a dual role in the X.-RL1 and AAhmed endometrium: (i) as a controller of the uterine vascular bed; and (ii) as an angiogenic and mitogenic mediator in regeneration of the endometrium after endometrial shedding. Alterations in the distribution of ANG and/or the activities of its receptors are likely to be involved in dysfunctional uterine bleeding. Higher ANG activities may be responsible for the increase in endometrial vascular density in Norplant-treated endometrium. However, the poor development of endometrial spiral arterioles with very low ANG activities around blood vessels may cause vascular dysfunction that leads to clinically irregular and prolonged bleeding and/or spotting in both endometrial hyperplasia and progestogen-only contraceptive users.
